Everolimus in advanced solid tumors: When to start, early or late

Tumori

Volumn 100, Issue 1, 2014, Pages

  Pusceddu, Sara ^a   Tessari, Anna ^a   Testa, Isabella ^a   Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast carcinoma; Everolimus; Neuroendocrine tumors; Renal carcinoma

Indexed keywords

EVEROLIMUS;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL DECISION MAKING; PERSONALIZED MEDICINE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TREATMENT OUTCOME;

EID: 84896973434     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/1430.15827     Document Type: Review

References (7)

1. Weber JD, Gutmann DH: Deconvoluting mTOR biology. Cell Cycle, 11: 236-248, 2012.
2. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 364: 514-523, 2011.
3. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372: 449-456, 2008.
4. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 366: 520-529, 2012.
5. Motzer RJ, Barrios HC, Kim TM, Falcon S, Cosgriff T, Harker WG, Pittman KB, Sabbatini R, Rha SY, Flaig TW, Page RD, Bavbek SE, Beck JT, Patel MP, Schiff E, Vaury A, Niolat J, Gogov S, Anak O, Knox J: Record 3: Phase 2 randomized trial comparing sequential first line everolimus (EVE) and second line sunitinib (SUN) versus first line SUN and second line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol, 31 (suppl): abstr 4504, 2013.
6. Procopio G, Pusceddu S, Buzzoni R: Sunitinib and everolimus in pancreatic neuroendocrine tumors. Tumori, 98: 394, 2012.
7. Procopio G, Verzoni E, Guadalupi V, Iacovelli R, Bajetta E: Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? Tumori, 96: 794-795, 2010.